BG Medicine, Inc. Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	32
ISBN Number	not applicable
Product Code	GMD04787

Price

£490.00
approximately: $749 | €546

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a BG Medicine, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1.1 List Of Tables
1.2 List of Figures
2 Company Overview
2.1 Key Information
2.2 Industry Outlook In Vitro Diagnostics
3 Major Products and Services
3.1 Overview
4 Competitors
5 Key Employees
6 Locations And Subsidiaries
6.1 Head Office
7 Recent Developments
7.1 Product News
- 7.1.1 Feb 07, 2008: BG Medicine Gains Rights To Test For Atherothrombosis Biomarker
- 7.1.2 Feb 05, 2008: BG Medicine Acquires Exclusive Commercial Rights To Biomarker Of Vascular Plaque
- 7.1.3 Sep 18, 2007: Spinal Muscular Atrophy Foundation And BG Medicine Announce Collaboration
- 7.1.4 May 23, 2007: BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker
- 7.1.5 May 16, 2007: BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration
8 BG Medicine, Inc. Pipeline Products
8.1 BG Medicine, Inc. Product Pipeline Analysis
- 8.1.1 BG Medicine, Inc. Pipeline Products By Equipment Type
- 8.1.2 BG Medicine, Inc. Pipeline Products By Development Stage
- 8.1.3 BG Medicine, Inc. Pipeline Products By Therapy Area
- 8.1.4 BG Medicine, Inc. Pipeline Products By News Summary
8.2 Liver Toxicity Biomarker
- 8.2.1 Product Description
- 8.2.2 Product Institution Details
- 8.2.3 Product Status
- 8.2.4 Product Milestone
8.3 Plasma biomarkers
- 8.3.1 Product Description
- 8.3.2 Product Institution Details
- 8.3.3 Product Status
- 8.3.4 Product Milestone
8.4 Biomarker-based Molecular Diagnostic Test For Congestive Heart Failure
- 8.4.1 Product Description
- 8.4.2 Product Status
- 8.4.3 Product Milestone
8.5 Biomarkers for multiple sclerosis
- 8.5.1 Product Description
- 8.5.2 Product Status
- 8.5.3 Product Milestone
8.6 Biomarker for acute atherothrombosis
- 8.6.1 Product Description
- 8.6.2 Product Status
- 8.6.3 Product Milestone
8.7 Biomarker for Herceptin treatment
- 8.7.1 Product Description
- 8.7.2 Product Status
8.8 Biomarker for early response to Tykerb
- 8.8.1 Product Description
- 8.8.2 Product Status
8.9 Biomarkers for Alzheimers disease
- 8.9.1 Product Description
- 8.9.2 Product Status
8.10 Markers for Tysabri efficacy
- 8.10.1 Product Description
- 8.10.2 Product Status
8.11 Biomarker of response to Avastin treatment
- 8.11.1 Product Description
- 8.11.2 Product Status
8.12 Molecular diagnostic test for Avandia treatment
- 8.12.1 Product Description
- 8.12.2 Product Status
8.13 Biomarker for detection of preeclampsia
- 8.13.1 Product Description
- 8.13.2 Product Status
8.14 Biomarkers for Enbrel and Remicade treatment
- 8.14.1 Product Description
- 8.14.2 Product Status
8.15 Diagnostic tests(acute atherothrombosis)
- 8.15.1 Product Description
- 8.15.2 Product Status
- 8.15.3 Product Milestone
9 Appendix
9.1 Methodology
- 9.1.1 Coverage
- 9.1.2 Secondary Research
- 9.1.3 Primary Research
- 9.1.4 Expert Panel Validation
9.2 Contact Us
9.3 About Global Markets Direct
9.4 Disclaimer
1 List of Tables
Table 1: BG Medicine, Inc.,Key Facts
Table 2: BG Medicine, Inc., Key Employees,
Table 3: BG Medicine, Inc. Pipeline Products by Equipment Type
Table 4: BG Medicine, Inc. Pipeline Products By Development Stage
Table 5: BG Medicine, Inc. Pipeline Products By Therapy Area
Table 6: BG Medicine, Inc. Pipeline Products By News Summaries
1.2 List of Figures
Figure 1: BG Medicine, Inc. Pipeline Products By Development Stage
Figure 2: Global Markets Direct Methodology